Key Takeaways
- • New Mountain Capital terminated negotiations with former executive Matt Holt over a proposed $32 billion acquisition of five healthcare technology portfolio companies (Datavant, Swoop, Machinify, Smarter Technologies, and Office Ally) that would have formed a new venture called Thoreau.
- • The deal structure included over $14 billion in proceeds to New Mountain's funds, $12 billion in debt financing commitments from JPMorgan Chase and Goldman Sachs, and equity commitments from multiple investors, but negotiations collapsed due to deferred purchase price components and unresolved debt structure concerns.
- • Matt Holt, president of private equity at New Mountain Capital for over two decades (joined 2001), departed the firm in December 2025 to pursue the independent health-tech venture, marking a significant exit for a star dealmaker in the sector.
- • The proposed platform was designed to leverage artificial intelligence across the five portfolio companies to reduce healthcare costs, representing a consolidated bet on AI-driven healthcare technology consolidation.
- • New Mountain cited prolonged negotiation cycles creating management distraction alongside governance concerns as reasons for terminating talks, signaling deal complexity and stakeholder alignment challenges in the $30+ billion transaction structure.
Summary
New Mountain Capital formally ended negotiations with former executive Matt Holt regarding a landmark healthcare technology acquisition that would have valued the transaction at approximately $32 billion. In a letter to clients distributed late Thursday, New Mountain outlined its decision to halt discussions following months of intensive deal development. Holt, who served as president of private equity at New Mountain Capital for more than two decades before departing in December 2025, had been pursuing the acquisition as the foundation for launching an independent venture.
The proposed transaction would have consolidated five New Mountain portfolio companies—Datavant, Swoop, Machinify, Smarter Technologies, and Office Ally—into a unified technology platform called Thoreau. The strategic rationale centered on using artificial intelligence to optimize healthcare cost reduction across the combined entity. According to sources familiar with the negotiations, the most recent proposal submitted the previous week would have delivered over $14 billion in proceeds to New Mountain's funds while securing more than $12 billion in debt financing commitments from JPMorgan Chase and Goldman Sachs, alongside equity commitments from multiple institutional investors.
However, New Mountain identified material obstacles that made proceeding untenable. The revised bid deferred several billion dollars of the purchase price into later tranches, and outstanding questions regarding debt structure and governance arrangements remained unresolved. Beyond these structural concerns, New Mountain cited the extended negotiation timeline as an ongoing distraction for portfolio company management, undermining operational focus. The deal underwent multiple revisions as Holt coordinated with healthcare entities, pension funds, and major financial institutions to construct financing packages capable of supporting the transaction scale.
The collapse represents a significant setback for one of the private equity sector's most prominent dealmakers. Holt's departure from New Mountain after two decades signaled confidence in his ability to execute an independent strategy, yet the complexity of orchestrating a $30+ billion carve-out from an established platform proved insurmountable within acceptable parameters for both parties. The termination underscores challenges inherent in mega-cap private equity transactions when governance structures, debt architecture, and deferred consideration mechanisms cannot achieve full alignment among multiple stakeholder constituencies.
The proposed transaction would have consolidated five New Mountain portfolio companies—Datavant, Swoop, Machinify, Smarter Technologies, and Office Ally—into a unified technology platform called Thoreau. The strategic rationale centered on using artificial intelligence to optimize healthcare cost reduction across the combined entity. According to sources familiar with the negotiations, the most recent proposal submitted the previous week would have delivered over $14 billion in proceeds to New Mountain's funds while securing more than $12 billion in debt financing commitments from JPMorgan Chase and Goldman Sachs, alongside equity commitments from multiple institutional investors.
However, New Mountain identified material obstacles that made proceeding untenable. The revised bid deferred several billion dollars of the purchase price into later tranches, and outstanding questions regarding debt structure and governance arrangements remained unresolved. Beyond these structural concerns, New Mountain cited the extended negotiation timeline as an ongoing distraction for portfolio company management, undermining operational focus. The deal underwent multiple revisions as Holt coordinated with healthcare entities, pension funds, and major financial institutions to construct financing packages capable of supporting the transaction scale.
The collapse represents a significant setback for one of the private equity sector's most prominent dealmakers. Holt's departure from New Mountain after two decades signaled confidence in his ability to execute an independent strategy, yet the complexity of orchestrating a $30+ billion carve-out from an established platform proved insurmountable within acceptable parameters for both parties. The termination underscores challenges inherent in mega-cap private equity transactions when governance structures, debt architecture, and deferred consideration mechanisms cannot achieve full alignment among multiple stakeholder constituencies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.